Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.
Publication/Presentation Date
9-1-2019
Abstract
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than 1 year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong candidate target due to its dependence on the pro-oncogenic mRNA stability factor HuR (
Volume
79
Issue
17
First Page
4491
Last Page
4502
ISSN
1538-7445
Published In/Presented At
Jain, A., Agostini, L. C., McCarthy, G. A., Chand, S. N., Ramirez, A., Nevler, A., Cozzitorto, J., Schultz, C. W., Lowder, C. Y., Smith, K. M., Waddell, I. D., Raitses-Gurevich, M., Stossel, C., Gorman, Y. G., Atias, D., Yeo, C. J., Winter, J. M., Olive, K. P., Golan, T., Pishvaian, M. J., … Brody, J. R. (2019). Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Cancer research, 79(17), 4491–4502. https://doi.org/10.1158/0008-5472.CAN-18-3645
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31273064
Department(s)
Administration and Leadership
Document Type
Article